EGFR and non-small cell lung carcinoma: In addition, a previous study indicated that AR is significantly over-expressed in non-responders, but undetectable in responders, which may biologically affect drug sensitivity and lead to the resistance of non–small cell lung cancer (NSCLC) cells to EGFR tyrosine kinase inhibitors in vitro [70].